Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 0.59 |
| ▸ | DRD3 | P35462 | 20/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644477 | 1.00 | DRD2 (0.59) | DRD2DRD3DRD4 | |
| SCHEMBL16406394 | 0.86 | DRD2 (0.46) | DRD2DRD3 | |
| SCHEMBL19358733 | 0.84 | DRD2 (0.61) | DRD2DRD3DRD4 | |
| SCHEMBL14494898 | 0.82 | DRD2 (0.67) | DRD2DRD3DRD4 | |
| SCHEMBL6820070 | 0.81 | DRD3 (0.57) | DRD2DRD3DRD4 | |
| SCHEMBL2782099 | 0.81 | DRD2 (0.61) | DRD2DRD3DRD4 | |
| SCHEMBL1194044 | 0.81 | DRD2 (0.61) | DRD2DRD3DRD4 | |
| SCHEMBL646496 | 0.79 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| SCHEMBL646497 | 0.79 | DRD2 (0.69) | DRD2DRD3DRD4 | |
| SCHEMBL1896873 | 0.79 | DRD2 (0.72) | DRD2DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| EP-3022179-B1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-11-15 | — | — | EP | disclosed |
| EP-3022179-B1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-11-15 | — | — | EP | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-07-07 | — | — | US | disclosed |
| EP-3022179-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | Fondazione Istituto Italiano Di Tecnologia (IT) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007615-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2015-01-22 | — | — | WO | disclosed |
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-10-02 | — | — | US | disclosed |
| US-8748608-B2 | 4-phenylpiperazine derivatives with functionalized linkers as dopamine D3 receptor selective ligands and methods of use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-06-10 | — | — | US | disclosed |
| US-8119642-B2 | Structurally rigid dopamine D3 receptor selective ligands and process for making them | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH AND HUMAN SERVICES | 2010-10-21 | — | — | US | disclosed |
| US-20100068138-A1 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM | NEWMAN AMY | 2010-03-18 | — | — | US | disclosed |
| US-7605259-B2 | N-(4-(4-(2,3 -dichlorophenyl)piperazin-1-yl)but-2-enyl)-1H-indole-2-carboxamide; imaging agents; tomography;diagnosis/medical/; selective, oral bioavailable drugs; nervous system disorders; central nervous system;oral administration; substance abuse ( cocaine/amphetamine); psychosis; Parkinson's | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH (US) | 2009-10-20 | — | — | US | disclosed |
| WO-2008153573-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20060106030-A1 | Structurally rigid dopamine d3 receptor selective ligands and process for making them | GOV'T OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-05-18 | — | — | US | disclosed |
| WO-2004024878-A2 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM | GOV'T OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267737-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, HTR3C | DRD2 2/4885DRD3 1/4885DRD4 4/4885 |
| US-20060106030-A1 | Structurally rigid dopamine d3 receptor selective ligands and process for making them | DRD3, OPRD1, DRD2 | DRD2 3/4885DRD3 1/4885DRD4 8/4885 |
| US-20140296249-A1 | 4-PHENYLPIPERAZINE DERIVATIVES WITH FUNCTIONALIZED LINKERS AS DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND METHODS OF USE | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885DRD4 6/4885 |
| US-20100068138-A1 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM | DRD3, OPRD1, DRD2 | DRD2 3/4885DRD3 1/4885DRD4 8/4885 |
| US-20160194296-A1 | PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR) | FAAH, FAAH2, FFAR3 | DRD2 9/4885DRD3 5/4885DRD4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.